Zhitong Finance App News, Baiyunshan (00874.HK) announced that on December 17, 2025, the buyer (Guangzhou Pharmaceutical, a subsidiary of the company) and the seller (Haizheng Pharmaceutical, an independent third party of the company) signed an equity transaction contract and supplementary agreement. According to the equity transaction contract and supplementary agreement, the buyer plans to acquire 100% of the shares of Zhejiang Pharmaceutical Industry Co., Ltd., at a consideration of approximately RMB 500.5 million. After the acquisition is completed, the buyer will hold 100% of the target company's shares.

Zhitong Finance App News, Baiyunshan (00874.HK) announced that on December 17, 2025, the buyer (Guangzhou Pharmaceutical, a subsidiary of the company) and the seller (Haizheng Pharmaceutical, an independent third party of the company) signed an equity transaction contract and supplementary agreement. According to the equity transaction contract and supplementary agreement, the buyer plans to acquire 100% of the shares of Zhejiang Pharmaceutical Industry Co., Ltd., at a consideration of approximately RMB 500.5 million. After the acquisition is completed, the buyer will hold 100% of the target company's shares.